With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’
Executive Summary
Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.
You may also be interested in...
Bausch + Lomb CEO Leaving 10 Weeks Following IPO, Month After Icahn Gains Two Board Seats
Joseph Papa steps down as chair and will remain at helm and on board until successor appointed. Guggenheim analysts reported representatives on B+L board for activist investor Carl Icahn appointed a month ago likely led to Papa’s exit.
Bausch Health Lubricates Bausch + Lomb's Pending Separation With Hydration Eye Drops Launch
Biotrue Hydration Boost contains glyercrin, available in the US as an ophthalmic remedy under an FDA OTC monograph. Launch is latest addition to Baush + Lomb consumer portfolio as Bausch Health prepares to make it a standalone firm.
Bausch CEO Papa Will Head Eye Health Biz Under Strategic Review
Bausch Health CEO Joseph Papa will move over to head separate Bausch + Lomb pure-play eye health business and is preparing a team for either a spin-off or initial public offering of the unit in the third quarter, the executive said during a first quarter earning call 4 May. Papa said a sale of the division, which includes consumer health eye drops and dietary supplements, is also possible.